OVERVIEW

State of the Art of Cancer Therapeutics: Focus on the Impact of Immunology Across Tumor is organized by City of Hope and will be held from Mar 26, 2019 to Mar 26, 2020.

Target Audience:
Community and institution-based medical oncologists, hematologists, surgical oncologists, interventional radiologists, pathologists and other healthcare providers involved in the management of patients with cancer. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credit™.

Description:
The rapidly evolving cancer treatment landscape calls for persistent and enhanced education of oncology and hematology clinicians (as well as interventional radiologists, pathologists, pharmacists, and other members of the multidisciplinary care team) who are challenged to stay current with the plethora of new agents and strategies that continue to emerge for a variety of cancer types and subtypes. Oncology practice offers numerous opportunities for personalized, or “precision” medicine, with a burgeoning array of exciting, novel, targeted therapies and immunotherapies that continue to emerge rapidly across a wide variety of tumor types and disease states.

The need for this education is vital, considering recent (and sobering) statistics from the American Cancer Society, estimating a total of 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in the United States in 2017. [ACSa] According to multiple sources, the cancer treatment landscape is progressing too quickly for many oncology clinicians—even those who specialize in the management of certain tumor types—to keep pace. Time pressures, stresses, and inefficiencies in the practice of medicine all limit clinicians’ ability to focus on new information. [IOM 2013] This educational initiative that provides a succinct update of the latest and most practical efficacy and safety data for new and emerging cancer treatments is critical to ensure that patients receive high-quality care that will optimize their outcomes.

Objectives:
At the end of this continuing medical education activity, participants should be able to:
• Describe the core science behind and implications of immuno-oncology as it relates to key biomarkers and pathways
• Discuss how the science of immuno-oncology affects treatment across tumor types, including emerging biomarkers and treatment options